Positherapy: Targeted nuclear therapy of breast cancer with 18F-2-deoxy-2-fluoro-D-glucose

Cancer Research

Volumn 65, Issue 3, 2005, Pages 698-702

  Moadel, Renee M ^a   Weldon, Richard H ^a   Katz, Ellen B ^a   Lu, Ping ^a   Mani, Joseph ^a   Stahl, Mark ^a   Blaufox, M Donald ^a   Pestell, Richard G ^b   Charron, Maureen J ^a   Dadachova, Ekaterina ^a  

^a ALBERT EINSTEIN COLLEGE OF MEDICINE   (United States)

^b GEORGETOWN UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

FLUORODEOXYGLUCOSE F 18; GLUCOSE TRANSPORTER; GLUCOSE TRANSPORTER 1; GLUCOSE TRANSPORTER 4; GLUCOSE TRANSPORTER 8; NOTCH RECEPTOR; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BREAST CANCER; CANCER CELL; CANCER SURVIVAL; CELL MEMBRANE; CONTROLLED STUDY; CYTOPLASM; DRUG HALF LIFE; DRUG UPTAKE; FEMALE; GROWTH RATE; IMMUNOBLOTTING; IMMUNOFLUORESCENCE; MAXIMUM TOLERATED DOSE; MOUSE; NECROSIS; NONHUMAN; NUDE MOUSE; POSITHERAPY; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN LOCALIZATION; THERAPY; TUMOR GROWTH; TUMOR XENOGRAFT;

ANIMALS; FEMALE; FLUORESCENT ANTIBODY TECHNIQUE; FLUORODEOXYGLUCOSE F18; GLUCOSE TRANSPORT PROTEINS, FACILITATIVE; GLUCOSE TRANSPORTER TYPE 1; GLUCOSE TRANSPORTER TYPE 4; IMMUNOBLOTTING; MAMMARY NEOPLASMS, EXPERIMENTAL; MICE; MICE, NUDE; MICE, TRANSGENIC; MONOSACCHARIDE TRANSPORT PROTEINS; MUSCLE PROTEINS; POSITRON-EMISSION TOMOGRAPHY; RADIOPHARMACEUTICALS;

EID: 13444263251     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (20)

1. Rohren EM, Turkington TG, Coleman KE. Clinical applications of PET in oncology. Radiology 2004;231:305-32.
2. Gallagher BM, Fowler JS, Gutterson NI, McGregor RR, Wan CN, Wolf AP. Metabolic trapping as a principal of radiopharmaceutical design: some factors responsible for biodistribution of 18F-2-deoxy-2-fluoro-D-glucose. J Nucl Med 1978;19:1154-61.
3. 18F-FDG) has a therapeutic potential in breast cancer. Breast Cancer Res 2003;5:199-205.
4. Fitzgerald K, Harrington A, Leder P. Ras pathway signals are required for notch-mediated oncogenesis. Oncogene 2000;19:191-8.
5. Weijzen S, Rizzo P, Braid M, et al. Activation of Notch-1 signaling maintains the neoplastic phenotype in human Ras-transformed cells. Nat Med 2002;8:979-86.
6. Joost HG, Thorens B. The extended GLUT-family of sugar/polyol transport facilitators: nomenclature, sequence characteristics, and potential function of its novel members. Mol Membr Biol. 2001;18:247-56.
7. Flier JS, Mueckler MM, Usher P, Lodish HF. Elevated levels of glucose transport and transporter messenger RNA are induced by ras or src oncogenes. Science 1987;235:1492-5.
8. Young AT, Dahl J, Hausdorff SF, Bauer PH, Birnbaum MJ, Benjamin TL. Phosphatidylinositol 3-kinase binding to polyoma virus middle tumor antigen mediates elevation of glucose transport by increasing translocation of the GLUT1 transporter. Proc Natl Acad Sci U S A 1995;92:11613-7.
9. Katz EB, Stenbit AE, Hatton K, DePinho R, Charron MJ. Cardiac and adipose tissue abnormalities but not diabetes in mice deficient in GLUT4. Nature 1995;377:151-5.
10. Gorovits N, Cui L, Busik JV, Ranalletta M, Hauguel de-Mouzon S, Charron MJ. Regulation of hepatic GLUT8 expression in normal and diabetic models. Endocrinology 2003;144:1703-11.
11. MacKeehan WL. Glycolysis, glutaminolysis and cell proliferation. Cell Biol Int Rep 1982;635-50.
12. Younes M, Brown RW, Mody DR, Fernandez L, Laucirica R. GLUT1 expression in human breast carcinoma: correlation with known prognostic markers. Anticancer Res 1995;15:2895-8.
13. Zamora-Leon SP, Golde DW, Concha II, et al. Expression of the fructose transporter GLUT5 in human breast cancer. Proc Natl Acad Sci U S A 1996;93:1847-52.
14. Medina RA, Meneses AM, Vera JC, et al. Estrogen and progesterone up-regulate glucose transporter expression in ZR-75-1 human breast cancer cells. Endocrinology 2003;144:4527-35.
15. Carayannopoulos MO, Chi MM, Cui Y, et al. GLUT8 is a glucose transporter responsible for insulin-stimulated glucose uptake in the blastocyst. Proc Natl Acad Sci U S A 2000;97:7313-8.
16. Bos R, van Der Hoeven JJ, van Der Wall E, et al. Biologic correlates of 18-fluorodeoxyglucose uptake in human breast cancer measured by positron emission tomography. J Clin Oncol 2002;20:379-87.
17. Lewis J, Laforest R, Buettner T, et al Copper-64-diacetyl-bis(N4- methylthiosemicarbazone): An agent for radiotherapy. Proc Natl Acad Sci U S A 2001;98:1206-11.
18. Xue LY, Butler NJ, Makrigiorgos GM, Adelstein SJ, Kassis AI. Bystander effect produced by radiolabeled tumor cells in vivo. Proc Natl Acad Sci U S A 2002;99:13765-70.
19. Rogers S, Docherty SE, Slavin JL, Henderson MA, Best JD. Differential expression of GLUT12 in breast cancer and normal breast tissue. Cancer Lett 2003;193:225-33.
20. Sistonen L, Holtta E, Lehvaslaiho H, Lehtola L, Alitalo K. Activation of the neu tyrosine kinase induces the fos/jun transcription factor complex, the glucose transporter and ornithine decarboxylase. J Cell Biol 1989;109:1911-9.